Company intelligence / Profile preview

Genetics Squared

Ann Arbor, Michigan, United States

Ownership: Private
Development stage: Other

Overview

Genetics Squared was a bioinformatics and predictive molecular diagnostics company that specialized in personalized medicine. The company developed a proprietary machine learning platform designed to analyze complex clinical and molecular data to predict patient responses to specific therapies. Its technology was primarily applied in oncology to identify biomarkers and develop diagnostic tests that guide treatment decisions. In 2011, the company's assets and intellectual property were acquired by Biodesix, where its platform was integrated to enhance the development of blood-based proteomic tests for lung cancer.

Therapeutic areas: Oncology
Modalities: DiagnosticSoftware
Industry: Molecular Diagnostics

Partnerships

Biodesix

Beyond the preview

Go deeper on Genetics Squared.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Genetics Squared.

Explore the full profile